2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Klatskin Tumor
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Adenocarcinoma
1
Interventions
Gemcitabine
113
Cisplatin
77
Oxaliplatin
46
pembrolizumab
35
Fluorouracil
33
Capecitabine
31
durvalumab
27
Leucovorin
27
lenvatinib
26
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Drug Therapy
13
Biopsy
13
Nivolumab
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
130-nm albumin-bound paclitaxel
11
pemigatinib
10
apatinib
10
Taxes
10
Radiotherapy
10
Floxuridine
10
Folfox protocol
9
Bevacizumab
9
S 1 (combination)
8
Platinum
8
Photochemotherapy
8
Liver Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
temoporfin
×
Clear all
NCT03003065
2023-08-22
PDT
Chinese University of Hong Kong
Phase 2
Completed
10 enrolled